What is the genomics lab software stack?
The genomics lab software stack is the set of software systems that carry a genomic test through its full lifecycle: order intake, order validation, sequencing handoff, the bioinformatics pipeline, variant interpretation, knowledge management, and clinical reporting. The stack works when the handoffs between those stages are automated, traceable, and compliant. It fails, quietly and expensively, when they are manual. The scope here is software, not your instruments or assays.
Why genomic test turnaround time is a software problem, not a sequencing problem
Once sequencing became fast and cheap, the bottleneck moved downstream. Variant interpretation is now a major bottleneck in clinical genomics workflows, and curating the evidence behind a single variant by hand can take several hours to days of expert time. The pattern repeats everywhere: intake teams re-key requisitions, operations teams chase orders that failed silently in transit, bioinformaticians learn a pipeline crashed only when a clinician calls, and lab directors wait months for a developer to change a report template. None of this is science, and all of it is software a lab can fix.
The accelerator idea is simple. These problems are the same lab after lab, so the software that solves them does not need to be reinvented each time. NonStop's genomics accelerators are built for this: proven, deployable components that, in NonStop's own engagements, remove an estimated 40 to 50 percent of the initial development effort, so the finished system reaches production sooner.
| Stack stage | Where the lab loses time | The accelerator you start with | NonStop estimate* |
|---|---|---|---|
| Order intake | Re-keying requisition forms by hand | OCR extraction plus schema validation, 20+ provider templates (SmartReq) | Under 2 min/form, near-zero entry errors |
| Order validation | EHR orders failing silently over Mirth Connect | FHIR R4/HL7 validation and dedup layer (Intergenix) | ~80% integration effort cut; 8–12 hrs/week saved |
| Bioinformatics pipeline | Failures found at the clinical end, not the pipeline end | Real-time observability across Nextflow, Snakemake, WDL, CWL (StrixFlow) | 4–8 hrs/day of debugging recovered |
| Variant interpretation | Manual ClinVar, gnomAD, OMIM queries and ACMG by hand | Human-in-the-loop evidence assembly on a GA4GH VRS store (Varion) | Review time to 30–60 min/case |
| Knowledge management | Classifications locked inside a vendor tool | Owned, versioned, queryable variant knowledge base (GENVAR) | ~60% of interpretation rework removed |
| Clinical reporting | Months-long developer cycles for report changes | Drag-and-drop builder with versioning and 21 CFR Part 11 audit (ReportStudio) | Report cycle to 1–2 weeks for lab staff |
*NonStop's impact figures are estimates that vary by engagement scope.
Order intake: stop transcribing requisitions
Intake teams re-key hundreds of forms a day across dozens of provider layouts. A transposed date of birth or a missing ICD code does not stay at intake; it propagates to billing and surfaces weeks later as a claim denial, and there is no scalable manual fix. NonStop's SmartReq accelerator reads printed, handwritten, and checkbox fields, validates each extraction against a schema before a human sees it, and runs on-premises so patient data never leaves the lab.
Order validation: catch the orders that fail silently
Electronic orders fail quietly. A share of EHR orders moving through Mirth Connect break on a missing insurance segment, a malformed HL7 message, or a duplicate retry, and nobody notices until a denial lands or a clinic calls. NonStop's Intergenix accelerator sits over Mirth Connect with bidirectional FHIR R4 and HL7 sync, deduplication, and field-level failure reporting that names exactly which order broke and why.
Bioinformatics pipeline: see the failure when it happens
A lab running Nextflow or Snakemake across HPC and cloud often has no single view of what is running, what failed, and why. A run dies overnight; the first sign is a clinician asking where a result is, and compute cost stays invisible until the cloud bill arrives. NonStop's StrixFlow accelerator adds step-level observability and cost-per-sample tracking, connecting to your existing bioinformatics pipelines without rewriting them.
Variant interpretation: hand the analyst back their hours
Interpretation is the heart of the test and, at scale, the main driver of turnaround time, yet much of it is mechanical evidence-gathering rather than judgment. NonStop's Varion accelerator assembles the evidence automatically and runs parallel scoring tracks, then presents the case for the analyst to weigh. No report issues without the qualified expert's approval. This is AI-assisted tertiary analysis that frees the scientist for the variants that genuinely need human judgment.
Knowledge management: own the judgment your lab accumulates
A lab's most valuable asset is its accumulated clinical judgment. When that lives inside a vendor platform, the lab cannot query it, migrate it cleanly, or build AI on it, and when an analyst leaves, their reasoning leaves too. NonStop's GENVAR accelerator treats every classification as a versioned, owned event on a GA4GH VRS canonical store and monitors ClinVar for changes. That matters clinically: reanalysis of existing data raises diagnostic yield by about 7 percent per year, so flagging variants for re-review turns a forgotten task into recovered diagnoses.
Clinical reporting: take the report off the developer's ticket queue
In many labs, every new panel or wording change triggers a three-to-four-month engineering cycle, and lab staff have no direct control over the tool they depend on daily. NonStop's ReportStudio accelerator gives them a drag-and-drop builder, maps pipeline output directly into report placeholders, and enforces template versioning with an approval workflow and a 21 CFR Part 11 audit trail. The lab director or clinical geneticist keeps the sign-off, and the clinical genomics workflow stops depending on a developer's backlog.
Build, buy, or accelerate: which is right for your lab
Building the full stack in-house gives you total control and costs you a year you may not have. Buying a closed end-to-end platform switches on faster but tends to lock your data and classifications inside a format you do not control, the exact trap GENVAR exists to avoid. Accelerating is the middle path: you start from validated components, customize them to your assays and compliance needs, and keep ownership of the result. For a lab under CAP/CLIA pressure and scaling volumes, that usually buys production speed without surrendering control of the data or the workflow.
What makes the whole stack work
Six accelerators are not a stack until a few principles hold across all of them. Own your data and knowledge, so you can query, migrate, and build on your own classifications and audit history. Keep PHI in your environment: healthcare has been the costliest sector for data breaches for 14 consecutive years, at an average of $7.42 million per breach in 2025, so self-hosted deployment is now the expectation, not a premium. Build compliance in, not on, because 21 CFR Part 11, HIPAA, CLIA/CAP, and ISO 27001 are architectural, and an accreditation review finds anything bolted on late. And integrate rather than replace, connecting over HL7/FHIR, Mirth Connect, and the existing LIMS and EHR, so you fix the gaps without tearing out what already works.
How long does it take to build clinical genomics software in-house versus using accelerators?
A full custom stack built from scratch is typically a multi-quarter engineering effort before turnaround improves. NonStop estimates its genomics accelerators remove 40 to 50 percent of that initial build effort by providing validated, deployable starting points, with the exact savings depending on assays, integrations, and compliance scope.
Are these genomics accelerators off-the-shelf products?
No. They are pre-built components a lab customizes and owns, deployed in its own environment. They shorten the path to production rather than replacing the engineering, validation, and sign-off that clinical use requires.
Can the accelerators connect to our existing LIMS, EHR, and pipelines?
Yes. They integrate over HL7 v2, FHIR R4, and Mirth Connect, and the pipeline layer connects to Nextflow, Snakemake, WDL, and CWL without rewriting your workflows.
Do AI-assisted accelerators replace the genetic analyst?
No. The AI assembles evidence and prioritizes candidates; the qualified analyst makes the classification and signs the report. No report issues without expert approval.
Which accelerator should a lab deploy first?
Start where the pain is sharpest and most measurable: intake errors causing claim denials, silent order failures, an interpretation backlog, or a slow report cycle. The first win funds the next stage.
Can these be deployed on-premises for PHI control?
Yes. Every accelerator supports self-hosted deployment, so PHI and genomic data stay inside the lab's infrastructure.
Find your slowest stage before you build anything
If your workflow is leaking time between systems, the first step is not a full rebuild. It is an honest look at where the gaps actually are across the seven stages above, and which one is worth closing first.
Get a personalized architecture review
NonStop offers a 45-minute architecture review to map your current genomics lab software stack and tell you exactly where accelerators can cut your build time, or where they cannot. Bring the stage that slows you down most.
Book the review- Variant interpretation bottleneck — SwissGenVar, PMC11204794 (2024)
- Manual curation hours-to-days per variant — PMC12099401 (2024)
- Reanalysis +7% diagnostic yield/year — Genome Alert!, medRxiv 2021.07.13.21260422
- Healthcare costliest breach sector in 14 years, $7.42M — IBM Cost of a Data Breach 2025